Novartis AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NVS research report →
Range $136 – $163
Price Chart
About the company
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
- CEO
- Vasant Narasimhan
- IPO
- 1996
- Employees
- 75,267
- HQ
- Basel, BS, CH
AI snapshot
Six angles, distilled from the data.
The stock is in a broad consolidation after a strong multi-year run, with price still below the 200-day average and only modestly above the 50-day. It sits well off the 52-week high, but the gap to the low has narrowed, suggesting a mature reset rather than a broken trend.
Street sentiment is cautious-to-balanced: the consensus is Hold, with 6 Buys, 17 Holds, and 2 Sells. The target cluster has firmed around $149.50 to $157.10, while recent changes were mostly reiterations and mixed target moves, not a broad bullish reset.
The earnings profile is constructive. Novartis has beaten EPS in 6 of the last 8 quarters, including 9.3% and 9.5% surprises in the last two reports, and next-year EPS estimates point higher to 9.93 from a 5.24 TTM base. Shareholders should watch whether revenue growth and margin discipline keep pace with that step-up.
No notable insider activity. The recent transactions table is empty, so there is no discretionary buying or selling signal to read into.
Profitability is strong, with a 75.2% gross margin, 33.98% operating margin, and 17.49% net margin. Growth is steady rather than explosive, with revenue up 4.7% year over year, while the balance sheet carries $35.38 billion of debt against $11.59 billion of cash and equivalents.
Novartis screens as a high-quality large-cap pharma name with better profitability than many peers, supported by a 24.33% ROE and 7.25% FCF yield. At 17.32x earnings, valuation is not cheap, but it is still anchored by durable cash generation and a diversified drug portfolio.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $284.18B
- P/E
- 30.30
- Fwd P/E
- 16.88
- PEG
- -1.04
- P/S
- 5.41
- P/B
- 7.99
- EV/EBITDA
- 15.00
- Div Yield
- 2.79%
- Gross Margin
- 74.30%
- Op Margin
- 30.47%
- Net Margin
- 18.06%
- ROE
- 24.24%
- ROIC
- 13.96%
Latest fiscal year · YoY change
- Revenue
- $56.67B+9.6%
- Gross Profit
- $42.98B+10.5%
- Op Income
- $17.64B
- Net Income
- $13.98B+17.1%
- EPS
- $7.21+21.8%
- OCF Growth
- +8.7%
- FCF Growth
- +27.5%
- 52W High
- $170.46
- 52W Low
- $125.88
- 50D MA
- $150.20
- 200D MA
- $152.68
- Beta
- 0.41
- RSI (14)
- 39
- Avg Volume
- 2.17M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Novartis beat expectations on sales and margins in Q3, raised full-year core operating income guidance, and highlighted strong momentum from priority brands and pipeline wins.· October 27, 2026
- Q3 net sales rose 4% to $14.5 billion, core operating income increased 10% to $6 billion, and core EPS grew 8% to $2.46.
- Core operating margin improved to 41.6%, up 2 percentage points year over year, helped by gross margin gains and SG&A productivity.
- Priority brands were a major driver, with Kisqali up 37%, Kesimpta up 22%, Pluvicto up 20%, Leqvio up 63%, Semblix up 67%, and Rhapsido showing strong launch momentum.
- Management raised full-year 2026 core operating income guidance to low-single-digit growth from a prior low-single-digit decline view, while keeping sales guidance at low-single-digit growth.
- The quarter also included mixed pipeline news: remibrutinib data were positive, while delgociptacine and pelacarsen had setbacks that led to a $1.9 billion partial impairment charge.
Novartis reported Q3 2026 net sales of $14.5 billion, up 4%; core operating income of $6 billion, up 10%; core operating margin of 41.6%, up 2 percentage points; and core EPS of $2.46, up 8%. Reported operating income was $1.8 billion, down 61%, and net income was $1.2 billion, down 71%, mainly due to higher R&D expense including a $1.9 billion partial impairment of delgociptacine. Free cash flow was $5.1 billion in the quarter, while first-9-month free cash flow was $14 billion. For full-year 2026, management now expects core operating income to be in line with low-single-digit growth, versus prior guidance for a low-single-digit decline, and still expects net sales to grow at low-single-digit rates. They also reiterated core net financial results of an expense of $1.7 billion and a core tax rate of around 16.5%.
Vasant Narasimhan said the quarter showed the company’s “replacement power,” with growth from launches and priority brands offsetting LOE pressure from products like Entresto. He emphasized that Novartis is seeing strong execution across multiple growth drivers and that the pipeline delivered important milestones, especially remibrutinib and Pluvicto. His tone was confident and constructive, with repeated emphasis that the company remains on track for its midterm growth framework and long-term outlook.
Mukul Mehta said the quarter benefited from operating discipline and productivity, with SG&A down 7% year over year in Q3 even as sales rose 4%. He cited gross margin improvement and SG&A efficiency as the main reasons core operating margin reached 41.6%, and he noted free cash flow of $5.1 billion in the quarter and $14 billion for the first nine months. On capital allocation, he said Novartis repurchased $2.8 billion of stock in the first nine months under the current $10 billion buyback program, with $4.9 billion still to execute.
Analysts focused on 2027 growth, SG&A durability, Pluvicto uptake, Leqvio outcomes readouts, Kisqali competition, and the post-HARBOR path for delgociptacine. Management said 2027 should face less generic headwind than 2026, but said detailed guidance will come in January and that Q4 will still reflect year-end spending and some gross-to-net dynamics. On Pluvicto, management said the new PSMA launch will take time, especially as physician behavior shifts, but they see no impact from draft radiation-related guidance and no change to peak sales outlook. On delgociptacine, they said they likely still need another phase 3 study and are reassessing next steps with regulators.
The bull case is that Novartis is successfully offsetting mature-product pressure with strong launches and broad-based growth across key brands. Management sounded upbeat on remibrutinib, Rhapsido, Kisqali, Pluvicto, and Leqvio, and said 2027 should benefit from fewer generic headwinds and continued growth drivers. The raised full-year profit outlook and 41.6% margin also support the view that the company is still improving profitability while funding pipeline investment.
The bear case is that several pipeline and development issues remain unresolved, including the $1.9 billion delgociptacine impairment, pelacarsen’s failure to meet its primary endpoint, and ongoing uncertainty around some future studies. Management also flagged that Q4 margins should come down seasonally and that 2026 still faces pressure from Entresto generic erosion and Xolair biosimilar effects on other revenue. For some launches, including Pluvicto and Rhapsido, management stressed that broader uptake and access expansion will take time, so growth may not be linear.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 96.9%
- Shares Outstanding
- 1.89B
- Float Shares
- 1.83B
of shares held by institutions
1,680 13F filers
Congressional trading
Senate and House stock disclosures for NVS, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Kevin HernHouse · OK01 | Sell | Aug 27, 26 | Filing → |
| Alan ArmstrongSenate | Buy | Mar 30, 26 | Filing → |
| Alan ArmstrongSenate | Buy | Mar 31, 26 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Oct 30, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Oct 30, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Oct 31, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Sep 25, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Sep 11, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Jun 17, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Jun 9, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Jul 22, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Jun 10, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Jun 11, 25 | Filing → |
| George WhitesidesHouse · CA27 | Sell | Mar 24, 25 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fisher Asset Management, LLC | 16.76M | ▲ 1.24M |
| Morgan Stanley | 8.44M | ▼ 289.60K |
| Dimensional Fund Advisors LP | 7.88M | ▼ 242.04K |
| Primecap Management Co | 6.59M | ▼ 6.66K |
| Loomis Sayles & Co L P | 4.83M | ▼ 405.19K |
| Bank Of America Corp | 4.56M | ▼ 349.08K |
| Goldman Sachs Group Inc | 3.30M | ▲ 316.30K |
| Blackrock, Inc. | 2.93M | ▼ 120.19K |
| Jpmorgan Chase & Co | 2.55M | ▲ 284.28K |
| Northern Trust Corp | 2.53M | ▼ 259.92K |
| Janus Henderson Group Ltd. | 2.52M | ▲ 2.52M |
| Envestnet Asset Management Inc | 2.35M | ▲ 16.67K |
Held by 92 ETFs
Biggest fund positions in NVS by dollar value.
Our NVS coverage
Recent articles, reports, and earnings notes.

Novartis (NVS): Growth Drivers Offset Entresto Erosion
Novartis is navigating Entresto generic pressure with strong growth from Kisqali, Pluvicto, Leqvio, and Kesimpta. The stock looks durable, but valuation and near-term earnings pressure keep the stance at Hold.

Gene Therapy Stocks That Turn Science Into Sales: 7 Picks
A countdown of seven gene therapy stocks spans commercial treatments, gene-editing platforms, rare-disease specialists, and diversified pharmaceutical exposure.

Novartis AG (NVS) falls 12.7% after Phase III setbacks
Novartis AG (NVS) falls sharply after two late-stage trial failures hit investor confidence. The selloff reflects lost pipeline value, especially for pelacarsen, even as the company’s core business remains profitable and growing.
Want a deeper read on NVS?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Novartis Reaffirms Sales Targets as Drug Trial Results and FDA Talks Loom
marketbeat.com · Nov 19
Novartis Says AI Is Speeding Drug Discovery and Trials, but Clinical Payoff Remains Unproven
marketbeat.com · Nov 19
Novartis CEO Vas Narasimhan on Anthropic IPO: I'm incredibly proud, and it's a very exciting day
youtube.com · Nov 19
3 Big Pharma Dividend Stocks Built for Retirement Income
247wallst.com · Nov 19
Novartis Targets 5% Annual Sales Growth Through 2031 Despite Patent Expirations
marketbeat.com · Nov 19
Novartis AG (NVS) Meet Management: Growth Outlook, Cash Flow and R&D Pipeline Transcript
seekingalpha.com · Nov 19
Novartis trims medium-term growth target, shares fall
reuters.com · Nov 19
Novartis bets on bigger blockbusters to power growth, forecasting 5% annual sales through 2031
cnbc.com · Nov 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 20, 2026 · Live quote · Not investment advice